BridgeMD
New treatment option for Venous Thromboembolism
Official title THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)
ClinicalTrials.gov ID: NCT05735639
What this study is testing
What is Dalteparin Sodium?
Dalteparin Sodium is an investigational medicine, being studied as a potential treatment for venous thromboembolism.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Endovenous interventions are keyhole operations for varicose veins that are carried out from within the vein itself. Varicose veins are enlarged veins close to the surface of the skin.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Adults (\>18 years)
- Scheduled to undergo endovenous intervention of truncal varicose veins under local anaesthesia
- Treatment technologies including radiofrequency, laser, mechanochemical, foam sclerotherapy and cyanoacrylate glue
You likely can't join if
- Clinical indication for therapeutic anticoagulation e.g., atrial fibrillation
- Previous personal or first-degree relative history of VTE
- Thrombophilia
- Female patients of childbearing potential who have a positive pregnancy test
- A history of allergy to heparins or direct oral anticoagulants
- A history of heparin-induced thrombocytopenia
See the full eligibility criteria
- Adults (\>18 years)
- Scheduled to undergo endovenous intervention of truncal varicose veins under local anaesthesia
- Treatment technologies including radiofrequency, laser, mechanochemical, foam sclerotherapy and cyanoacrylate glue
- Clinical indication for therapeutic anticoagulation e.g., atrial fibrillation
- Previous personal or first-degree relative history of VTE
- Thrombophilia
- Female patients of childbearing potential who have a positive pregnancy test
- A history of allergy to heparins or direct oral anticoagulants
- A history of heparin-induced thrombocytopenia
- Inherited and acquired bleeding disorders
- Evidence of active bleeding
- Concomitant major health problems such as active cancer and chronic renal and/or liver impairment
- Known thrombocytopenia (platelets known to be less than 50 x 109 /l)
- Surgery or major trauma in the previous 90 days
- Recent ischemic stroke in the previous 90 days
- Inability to provide consent
The study team makes the final eligibility decision.
Where it's taking place
- London, United Kingdom
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include London, United Kingdom. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.